Lyra Therapeutics (LYRA) Share-based Compensation (2019 - 2025)

Lyra Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $562000.0 in Q4 2025.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $562000.0 in Q4 2025; TTM through Dec 2025 was $15.1 million, a 48.1% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 81.22% from the prior year.
• Share-based Compensation was $562000.0 for Q4 2025 at Lyra Therapeutics, up from $68558.0 in the prior quarter.
• The five-year high for Share-based Compensation was $13.8 million in Q4 2023, with the low at $68558.0 in Q3 2025.
• Average Share-based Compensation over 5 years is $4.4 million, with a median of $4.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 682.64% in 2023, then slumped 98.93% in 2025.
• Over 5 years, Share-based Compensation stood at $782000.0 in 2021, then jumped by 124.68% to $1.8 million in 2022, then jumped by 682.64% to $13.8 million in 2023, then sank by 53.55% to $6.4 million in 2024, then sank by 91.2% to $562000.0 in 2025.
• The last three Share-based Compensation figures came in at $562000.0 (Q4 2025), $68558.0 (Q3 2025), and $914000.0 (Q2 2025), per Business Quant data.